Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea-Japan collaborative study group trial

Yeul Hong Kim, Kensei Yamaguchi, Yung Jue Bang, Hiroya Takiuchi, Won Ki Kang, Atsushi Sato, Yoon Koo Kang, Junichi Sakamoto, Chigusa Abe, Yuh Sakata

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Benefits of chemotherapy have generally been modest in gastric cancer, although those regimens developed more recently have produced higher response rates. Paclitaxel plus cisplatin is one such regimen and divided administration of paclitaxel has been suggested to be associated with lower neurological and hematologic toxicities and be able to achieve higher paclitaxel dose intensities than paclitaxel administration at 175 mg/m 2 every 3 weeks. This study was undertaked to assess the efficacy and toxicity of a biweekly paclitaxel and cisplatin combination treatment in advanced gastric cancer. Methods: Twenty-five patients from Japan and Korea, 50 patients in total, were entered into this trial which was conducted from October 2004 to June 2005. Median age of the patients was 57 years (range: 26-78). Paclitaxel 140 mg/m 2 was administered intravenously on days 1 and 15 of each 4-week cycle. Cisplatin 30 mg/m 2 was also administered on days 1 and 15 with standard hydration. A total of 278 courses of treatment (two treatment courses per cycle) were conducted for 50 patients. The median number of treatment cycles per patient was two with a range of one to six. Results: Nine of the 50 patients responded to the treatment, with an overall objective response rate of 18% (95% CI, 12-41), which included one complete response. Two patients were not evaluable and 14 patients had stable disease as best response. The median survival duration of the 50 patients was 333 days (range: 52-637+ days). The main toxicity was neutropenia. Significant toxicity (NCI-CTC grade 3 or 4) included neutropenia in 19 patients (38%), anorexia in four (8%), infection in three (6%), anemia in three (6%), and abdominal pain in three (6%). Conclusions: Biweekly paclitaxel and cisplatin combination chemotherapy showed modest activity in advanced gastric carcinoma with a favorable toxicity pattern.

Original languageEnglish
Pages (from-to)501-508
Number of pages8
JournalJapanese Journal of Clinical Oncology
Volume37
Issue number7
DOIs
Publication statusPublished - 2007 Jul 1

Fingerprint

Korea
Combination Drug Therapy
Stomach Neoplasms
Japan
Paclitaxel
Neutropenia
TP protocol
Therapeutics
Anorexia
Abdominal Pain
Cisplatin
Anemia
Stomach
Carcinoma
Drug Therapy
Survival

Keywords

  • Cisplatin
  • Combination chemotherapy
  • Gastric cancer
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology

Cite this

Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer : Korea-Japan collaborative study group trial. / Kim, Yeul Hong; Yamaguchi, Kensei; Bang, Yung Jue; Takiuchi, Hiroya; Kang, Won Ki; Sato, Atsushi; Kang, Yoon Koo; Sakamoto, Junichi; Abe, Chigusa; Sakata, Yuh.

In: Japanese Journal of Clinical Oncology, Vol. 37, No. 7, 01.07.2007, p. 501-508.

Research output: Contribution to journalArticle

Kim, Yeul Hong ; Yamaguchi, Kensei ; Bang, Yung Jue ; Takiuchi, Hiroya ; Kang, Won Ki ; Sato, Atsushi ; Kang, Yoon Koo ; Sakamoto, Junichi ; Abe, Chigusa ; Sakata, Yuh. / Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer : Korea-Japan collaborative study group trial. In: Japanese Journal of Clinical Oncology. 2007 ; Vol. 37, No. 7. pp. 501-508.
@article{7f6471abc3cd41558d74f6918cedf157,
title = "Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea-Japan collaborative study group trial",
abstract = "Background: Benefits of chemotherapy have generally been modest in gastric cancer, although those regimens developed more recently have produced higher response rates. Paclitaxel plus cisplatin is one such regimen and divided administration of paclitaxel has been suggested to be associated with lower neurological and hematologic toxicities and be able to achieve higher paclitaxel dose intensities than paclitaxel administration at 175 mg/m 2 every 3 weeks. This study was undertaked to assess the efficacy and toxicity of a biweekly paclitaxel and cisplatin combination treatment in advanced gastric cancer. Methods: Twenty-five patients from Japan and Korea, 50 patients in total, were entered into this trial which was conducted from October 2004 to June 2005. Median age of the patients was 57 years (range: 26-78). Paclitaxel 140 mg/m 2 was administered intravenously on days 1 and 15 of each 4-week cycle. Cisplatin 30 mg/m 2 was also administered on days 1 and 15 with standard hydration. A total of 278 courses of treatment (two treatment courses per cycle) were conducted for 50 patients. The median number of treatment cycles per patient was two with a range of one to six. Results: Nine of the 50 patients responded to the treatment, with an overall objective response rate of 18{\%} (95{\%} CI, 12-41), which included one complete response. Two patients were not evaluable and 14 patients had stable disease as best response. The median survival duration of the 50 patients was 333 days (range: 52-637+ days). The main toxicity was neutropenia. Significant toxicity (NCI-CTC grade 3 or 4) included neutropenia in 19 patients (38{\%}), anorexia in four (8{\%}), infection in three (6{\%}), anemia in three (6{\%}), and abdominal pain in three (6{\%}). Conclusions: Biweekly paclitaxel and cisplatin combination chemotherapy showed modest activity in advanced gastric carcinoma with a favorable toxicity pattern.",
keywords = "Cisplatin, Combination chemotherapy, Gastric cancer, Paclitaxel",
author = "Kim, {Yeul Hong} and Kensei Yamaguchi and Bang, {Yung Jue} and Hiroya Takiuchi and Kang, {Won Ki} and Atsushi Sato and Kang, {Yoon Koo} and Junichi Sakamoto and Chigusa Abe and Yuh Sakata",
year = "2007",
month = "7",
day = "1",
doi = "10.1093/jjco/hym054",
language = "English",
volume = "37",
pages = "501--508",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer

T2 - Korea-Japan collaborative study group trial

AU - Kim, Yeul Hong

AU - Yamaguchi, Kensei

AU - Bang, Yung Jue

AU - Takiuchi, Hiroya

AU - Kang, Won Ki

AU - Sato, Atsushi

AU - Kang, Yoon Koo

AU - Sakamoto, Junichi

AU - Abe, Chigusa

AU - Sakata, Yuh

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Background: Benefits of chemotherapy have generally been modest in gastric cancer, although those regimens developed more recently have produced higher response rates. Paclitaxel plus cisplatin is one such regimen and divided administration of paclitaxel has been suggested to be associated with lower neurological and hematologic toxicities and be able to achieve higher paclitaxel dose intensities than paclitaxel administration at 175 mg/m 2 every 3 weeks. This study was undertaked to assess the efficacy and toxicity of a biweekly paclitaxel and cisplatin combination treatment in advanced gastric cancer. Methods: Twenty-five patients from Japan and Korea, 50 patients in total, were entered into this trial which was conducted from October 2004 to June 2005. Median age of the patients was 57 years (range: 26-78). Paclitaxel 140 mg/m 2 was administered intravenously on days 1 and 15 of each 4-week cycle. Cisplatin 30 mg/m 2 was also administered on days 1 and 15 with standard hydration. A total of 278 courses of treatment (two treatment courses per cycle) were conducted for 50 patients. The median number of treatment cycles per patient was two with a range of one to six. Results: Nine of the 50 patients responded to the treatment, with an overall objective response rate of 18% (95% CI, 12-41), which included one complete response. Two patients were not evaluable and 14 patients had stable disease as best response. The median survival duration of the 50 patients was 333 days (range: 52-637+ days). The main toxicity was neutropenia. Significant toxicity (NCI-CTC grade 3 or 4) included neutropenia in 19 patients (38%), anorexia in four (8%), infection in three (6%), anemia in three (6%), and abdominal pain in three (6%). Conclusions: Biweekly paclitaxel and cisplatin combination chemotherapy showed modest activity in advanced gastric carcinoma with a favorable toxicity pattern.

AB - Background: Benefits of chemotherapy have generally been modest in gastric cancer, although those regimens developed more recently have produced higher response rates. Paclitaxel plus cisplatin is one such regimen and divided administration of paclitaxel has been suggested to be associated with lower neurological and hematologic toxicities and be able to achieve higher paclitaxel dose intensities than paclitaxel administration at 175 mg/m 2 every 3 weeks. This study was undertaked to assess the efficacy and toxicity of a biweekly paclitaxel and cisplatin combination treatment in advanced gastric cancer. Methods: Twenty-five patients from Japan and Korea, 50 patients in total, were entered into this trial which was conducted from October 2004 to June 2005. Median age of the patients was 57 years (range: 26-78). Paclitaxel 140 mg/m 2 was administered intravenously on days 1 and 15 of each 4-week cycle. Cisplatin 30 mg/m 2 was also administered on days 1 and 15 with standard hydration. A total of 278 courses of treatment (two treatment courses per cycle) were conducted for 50 patients. The median number of treatment cycles per patient was two with a range of one to six. Results: Nine of the 50 patients responded to the treatment, with an overall objective response rate of 18% (95% CI, 12-41), which included one complete response. Two patients were not evaluable and 14 patients had stable disease as best response. The median survival duration of the 50 patients was 333 days (range: 52-637+ days). The main toxicity was neutropenia. Significant toxicity (NCI-CTC grade 3 or 4) included neutropenia in 19 patients (38%), anorexia in four (8%), infection in three (6%), anemia in three (6%), and abdominal pain in three (6%). Conclusions: Biweekly paclitaxel and cisplatin combination chemotherapy showed modest activity in advanced gastric carcinoma with a favorable toxicity pattern.

KW - Cisplatin

KW - Combination chemotherapy

KW - Gastric cancer

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=34548351282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548351282&partnerID=8YFLogxK

U2 - 10.1093/jjco/hym054

DO - 10.1093/jjco/hym054

M3 - Article

C2 - 17673470

AN - SCOPUS:34548351282

VL - 37

SP - 501

EP - 508

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 7

ER -